Draupnir
Founded 2017 · 19 employees on LinkedIn · 3 known investors
Draupnir Bio develops oral small-molecule degraders of extracellular and membrane-bound pathogenic proteins using a proprietary platform that targets lysosome receptors, extending targeted protein degradation (TPD). The biotech company focuses on drug discovery for diseases driven by extracellular proteins.
Investors · 3
Frequently asked questions
- What does Draupnir do?
- Draupnir Bio develops oral small-molecule degraders of extracellular and membrane-bound pathogenic proteins using a proprietary platform that targets lysosome receptors, extending targeted protein degradation (TPD). The biotech company focuses on drug discovery for diseases driven by extracellular proteins.
- Who are Draupnir's investors?
- Draupnir's investors include Gilde Healthcare, MC Healthcare Ventures, Inkef.